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POLIMORFISME GEN HFE PADA ORANG MELAYU 
ABSTRAK 
Variasi gen hemokromatosis (HFE) telah dilaporkan dapat merencatkan 
peranan hepcidin, mengakibatkan gangguan genetik autosomal yang disebut 
hemokromatosis keturunan (HH).  Variasi genetik ini merangkumi C282Y, H63D, dan 
S65C yang telah banyak dikaji di Eropah dan tidak ada untuk penduduk Malaysia.  
Tujuan kajian ini adalah untuk menilai variasi gen HFE pada orang Melayu.  Sebanyak 
35 sampel darah dikumpulkan dan genotip untuk C282Y, H63D, dan S65C 
menggunakan polimorfisme panjang sekatan reaksi-sekatan reaksi-polimerase (PCR-
RFLP).  Hasil kajian menunjukkan bahawa taburan frekuensi heterozigot H63D 
(5.71%) adalah dua kali lebih tinggi daripada heterozigot untuk S65C (2.86%).  Walau 
bagaimanapun, tidak ada individu Melayu yang homozigot atau heterozigot untuk 
C282Y.  Oleh itu, risiko HH pada orang Melayu rendah berbanding dengan orang 
Eropah yang mempunyai frekuensi tinggi alel dan genotip C282Y, H63D, dan S65C.  
Kajian masa depan harus merangkumi kumpulan populasi lain di Malaysia untuk 
penjelasan struktur populasi yang lebih baik dan risiko untuk mengembangkan HH di 
negara ini.  
xiv 
HFE GENE POLYMORPHISMS IN MALAYS 
ABSTRACT 
Variations in haemochromatosis gene (HFE) have been reported to inhibit the 
role of hepcidin, resulting in an autosomal genetic disorder called hereditary 
haemochromatosis (HH). These genetic variations include C282Y, H63D, and S65C 
which have been largely studied in Europeans and none for the Malaysian population.  
The aim of this study is to evaluate variations within the HFE gene in Malays. A total 
of 35 blood samples were collected and genotyped for C282Y, H63D, and S65C using 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). 
The findings of the study showed that the frequency distribution of heterozygous 
H63D (5.71%) was twice higher than those heterozygous for S65C (2.86%). However, 
no Malay individuals were homozygous or heterozygous for C282Y.  Therefore, risk 
for HH in Malays is low as compared with Europeans which have high frequencies of 
C282Y, H63D, and S65C alleles and genotypes. Future study should include other 
population groups in Malaysia for better elucidation of population structure and risk 
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CHAPTER 1  
 
INTRODUCTION 
1.1 Background of study 
The human genome consists thousands of polymorphic genes (Wain et al., 
2002), including cytokine, human leukocyte antigen (HLA), killer cell 
immunoglobulin-like receptor (KIR), major histocompatibility complex class I chain-
related gene A (MICA) and homeostatic iron regulator or haemochromatosis gene 
(Kumánovics et al., 2003; Reuben et al., 2017). The haemochromatosis gene (HFE) is 
a major histocompatibility complex (MHC) class I protein located on the short arm of 
chromosome 6 (6p22.2) that regulates the amount of iron in human body (Barton et 
al., 2015; Harrison and Bacon, 2005). In 1996, Feder et al. identified HFE gene and 
its mutation that contributed to a medical disorder known as hereditary 
haemochromatosis (HH). HH is a condition where iron is overloaded in internal organs 
such as heart, liver and pancreas (Barton and Edwards, 2018; Bellissimo and Agarwal, 
2016; Milman et al., 2019). 
Many studies have shown the associations between HFE mutations and HH 
(Alves et al., 2016; Canavesi et al., 2012; Hollerer et al., 2017; Jin et al., 2010; Juzėnas 
et al., 2016). Such studies also revealed unique frequency distributions of HFE gene 
variants between people of different ethnicities and their risk profiles to HH (Ali et al., 
2018; Barton et al., 2015; Merryweather-Clarke et al., 1997; Spínola et al., 2011; 
Viprakasit et al., 2004). The HH is mainly caused by the homozygous C282Y SNP 
(Allen et al., 2008). Moreover, H63D homozygous or compound heterozygote 
(C282Y/H63D or C282Y/S65C) genotypes might cause mild HH for those with 
existing medical conditions (viral hepatitis and non-alcohol fatty liver disease) and 
unhealthy lifestyle (alcoholism) (Allen et al., 2008; Gurrin et al., 2009; Walsh et al., 
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2006). Therefore, the present screening of HFE gene variants in Malays is essential as 
it will provide for the first time C282Y, H63D and S65C population data for this ethnic 
group and can be used for HH risk assessments. 
1.2 Rationale of study 
HFE gene codes the hepcidin protein that regulates iron uptake in human body 
(Loréal et al., 2018). Mutations in the HFE gene might cause iron overload and lead 
to HH (Spínola et al., 2011). HFE gene polymorphisms (C282Y, H63D and S65C) 
were uniquely distributed in unrelated ethnic populations worldwide (Barton et al., 
2015; Distante et al., 2004), yet no such data is available for any of the Malaysian 
population groups. Therefore, this study aims to provide frequency distributions of 
C282Y, H63D and S65C HFE single nucleotide polymorphisms (SNPs) in Malays and 
use the generated SNP datasets for estimating risks of developing HH in this ethnic 
group.
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1.3 Objectives 
1.1 General objective 
1. To study variations of HFE gene in Malays. 
1.2 Specific objectives 
2. To provide frequency distributions of C282Y, H63D and S65C HFE gene 
SNPs in Malays. 
3. To compare frequencies of C282Y, H63D, and S65C in Malays and other 
populations characterised for these HFE gene SNPs. 
4. To estimate the risk of HH associated with C282Y, H63D, and S65C 
mutations in Malays.
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CHAPTER 2  
 
LITERATURE REVIEW 
2.1 Haemochromatosis gene (HFE) 
The HFE gene code for hepcidin protein that involves in regulating iron intake 
in human body (Loréal et al., 2018; Nemeth and Ganz, 2009). Feder et al. (1996) used 
a positional cloning technique to examine DNA specimens from a cohort of 178 
Caucasian HH patients. The study identified two missense mutations in HFE gene; 
C282Y (rs1800562) and H63D (rs1799945) in exon 4 and 2, respectively.  Feder et al. 
further observed that most of the patients were homozygous for C282Y arising from 
the transformation of guanine at nucleotide 845 to adenine (845G→A). Few other 
patients were either H63D homozygous or C282Y/H63D compound heterozygous. 
The H63D SNP resulted in nucleotide substitution at position 187 from cytosine to 
guanine (187C→G) (Feder et al., 1996; Katsarou et al., 2019; Le Gac and Férec, 
2005). The identified gene was referred as HLA-H because it is close to the major 
histocompatibility complex (MHC) class I gene cluster on the short arm of 
chromosome 6. In 1997, the HUGO Gene Nomenclature Committee approved a new 
nomenclature for the HLA-H gene and later known as haemochromatosis (HFE) gene 
(Bodmer et al., 1997). 
A third mutation (S65C) within HFE gene was reported in a sample population 
of 711 HH patients (Mura et al., 1999). The S65C (rs1800730) is located at nucleotide 
position 193 in exon 2 of the HFE gene and replaces adenine with thymidine 
(193A→T) (Mura et al., 1999). 
A number of studies of HFE gene SNPs were performed in Asians to determine 
the most prevalent mutation (C282Y, H63D, and S65C) in the population (Ali et al., 
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2018; Khusainova et al., 2013; Lin et al., 2007; Merryweather-Clarke et al., 1997; 
Pointon et al., 2003). In 1997, a studied population of 457 Asians reported C282Y and 
H63D mutations in Asia (Merryweather-Clarke et al., 1997). In addition, C282Y and 
H63D alleles were also reported in North American HFE gene mutation study that 
recruited 12,772 Asians (Adams et al., 2005). The presence of S65C SNP was 
determined in Asians but found to absent in a studied population of 314 Vietnamese 
who lived in Vietnam. A similar report of no S65C mutation was reported in a study 
of HFE gene SNP in 395 Chinese Han in China (Lin et al., 2007). 
2.2 HFE structure and function 
The 12 kb HFE gene is located at chromosome 6p22.2p (Figure 2.1). The HFE 
gene has seven exons, which code a predicted 343-amino acid protein. The protein 
contains a signal sequence, peptide-binding domains (α1, α2 and α3), a transmembrane 
domain (TM), and a small cytoplasmic (cyto) part. The α1 and α2 domains are the 
receptor-binding sites of extracellular transferrin that associate with transferrin 
receptor 1 (TFR1) while the α3 domain is the immunoglobulin-like region that binds 
transferrin receptor 2 (TFR2). HFE protein binds to beta 2-microglobulin (β2M) and 
controls hepcidin expression (Figure 2.2) (Barton et al., 2015; Chua et al., 2007; 
Griffiths, 2007; Santos et al., 2010). 
Hepcidin produced in the liver regulates the uptake of iron and controls the 
presence of ferroportin which carries iron from the duodenum into the bloodstream. 
Therefore, the signalling pathways should be preserved for the interaction of the HFE 
protein and transferrin receptor 2 (TFR2) (Utzschneider and Kowdley, 2010). 
Nevertheless, HFE mutation inhibits the formation of disulfide bonds in the protein’s 
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α3 region, thus disrupting the pathway to engage with β2M (Feder et al., 1997; Lebrón 
et al., 1998).  
The disruption of the pathway would prevent the adequate synthesis of 
hepcidin (Figure 2.3) (Corradini et al., 2009; Utzschneider and Kowdley, 2010), thus 
favouring the accumulation of iron leading to iron overload that may aggravate into 
HH (Cançado and Chiattone, 2010; Murphree et al., 2020; Pietrangelo, 2015; Porto et 
al., 2016). The risk of developing severe conditions such as porphyria cutanea tarda 
(Barton and Edwards, 2016; Egger et al., 2002), cirrhosis (Barton et al., 2018), 
diabetes mellitus (Jennison and Wainwright, 2018; Raju and Venkataramappa, 2018), 
cardiac diseases (Rasmussen et al., 2001; Sumi et al., 2020), hepatocellular carcinoma 
and cancers (Abraham et al., 2005; Jayachandran et al., 2020; Jin et al., 2011; Lv et 
al., 2016; Robinson et al., 2005) increases if HH is left untreated (Crownover and 
Covey, 2013; Gabriková et al., 2012). 
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Figure 2.1: Schema shows location of the HFE gene on the short arm of 




Figure 2.2: Structure of HFE with the extracellular protein domains (α1 and α2) 
and the β2M associated with the immunoglobulin-like region (α3). Figure modified 




Figure 2.3: HFE protein and TFR2 signalling pathway. Figure modified from 
Utzschneider and Kowdley (2010).
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2.3 Prevalence of HFE gene SNPs 
The most common HFE SNP associated with HH is the C282Y (Gurrin et al., 
2009). This HFE SNP is typically high among Europeans but low or absent among 
non-European populations (Ali et al., 2018; Merryweather-Clarke et al., 1997). 
A second mutation, H63D, was reported in 5% of HH patients (1% were 
homozygote for H63D while 4% heterozygote compound of C282Y/H63D) (Adams, 
2015). The H63D mutation, by comparison, is relatively more common in worldwide 
populations with the highest recorded among Europeans (de Juan et al., 2001) and the 
lowest in Southeast Asia, Africa, Central and South America populations (Khusainova 
et al., 2013). 
A third mutation, S65C, is infrequently linked to severe iron overload and has 
therefore not been extensively investigated (Aranda et al., 2010; Brissot et al., 2017; 
Holmström et al., 2002; Mura et al., 1999; Muro et al., 2007). Individuals homozygous 
for S65C or compound heterozygote (C282Y/S65C) are associated with mild HH 
symptoms such as joint pain, fatigue, unintended weight loss, abnormal liver 
enlargement and weakness (Alexander and Kowdley, 2009; Ayonrinde et al., 2008; 
Cheng et al., 2009; Gurrin et al., 2009). 
2.3.1 Hereditary haemochromatosis 
Hereditary haemochromatosis (HH) is a genetic blood disorder associated with 
iron metabolism (Pantopoulos, 2018).  The hereditary disorder caused failure of the 
body to eliminate the excess iron obtained from food after absorption due to the 
inefficiency of the excretory mechanism. Consequently, this excess iron leads to a state 
of over-accumulation, which is harmful to cells. Usually, this clinical disease 
10 
manifestation is typically associated with C282Y mutation in HFE gene and it can be 
fatal if lately detected and untreated (Katsarou et al., 2016). Katsarou et al. (2016) 
reported that 3-5 individuals in a 1,000 population are C282Y homozygous in North-
western Europe populations.  
HH affects people all over the world (Shiono et al., 2001), most notably the 
Northern European origins (Bacon et al., 2011; Juzėnas et al., 2016; Tsui et al., 2000; 
Wallace and Subramaniam, 2016). HH is commonly asymptomatic and primarily 
affects adult males compared to females. Menstruation is a possible explanation for 
this late phenomenon in women (Al Wayli et al., 2011; Katsarou et al., 2016). Clinical 
symptoms appear in men at and after the age of 40 (Puntarulo, 2005).  
Genetic screening of HFE gene is thus essential because it will allow for early 
treatment of HH (Bassett, 2010; Brissot et al., 2008). Phlebotomy therapy prevents 
disease development and normalises iron level (Asimakopoulou et al., 2017; Koshy et 
al., 2020; Kowdley et al., 2019; Salgia and Brown, 2015). Tables 2.1 and 2.2 show the 
genotype and allele frequencies for C282Y, H63D and S65C mutations across the 
world.
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Table 2.1: Genotype frequencies of C282Y, H63D, and S65C mutations in the HFE gene  






















0.00 0.00 32.00 3.90 1.30 0.00 0.65 0.00 0.65 Spínola et al. (2011) 
Espírito Santo, 
Brazil 
3.33 0.00 20.83 0.83 0.83 0.00 0.00 0.00 0.83 Alves et al. (2016) 
Chinese Han 0.00 0.00 4.60 0.00 0.00 0.00 0.00 0.00 0.00 Lin et al. (2007) 
Netherlands 12.70 0.30 23.60 2.20 0.00 0.00 0.00 0.00 0.00 Cobbaert et al. (2012) 
Jordanian Arab 0.00 0.00 19.80 1.90 0.00 0.00 0.00 0.00 0.00 Alkhateeb et al. (2013) 
Thai, Thailand 0.00 0.00 20.00 1.00 0.00 0.00 0.00 0.00 0.00 Viprakasit et al. (2004) 
Czech Republic 6.86 0.00 26.61 1.67 2.49 0.00 1.87 0.00 0.42 Čimburová et al. (2005 
Pakistanis, UK 0.00 0.00 4.00 0.50 0.00 0.00 0.00 0.00 0.00 Ali et al. (2018) 
Iranian 1.20 0.00 8.50 0.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2006) 
Turkic 0.80 0.00 15.20 1.10 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2006) 
Lithuanian 5.10 0.10 26.70 2.60 3.70 0.00 1.19 0.10 0.40 Kucinskas et al. (2012) 
Belarusian 0.00 0.00 25.00 8.30 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
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Table 2.1: Cont. 






















3.75 0.00 25.62 1.25 0.62 0.00 0.63 0.00 0.00 Leão et al. (2014) 
Ukrainian 0.00 0.00 25.50 2.10 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Moldavian 0.00 0.00 19.10 0.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Karelian 0.00 0.00 19.00 1.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Volga–Ural 0.00 0.00 21.70 1.80 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Kazakh 0.00 0.00 15.50 0.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Uzbek 0.00 0.00 11.10 0.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Uighur 0.00 0.00 16.40 0.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Kirghiz 0.00 0.00 16.10 0.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Turkmen 0.00 0.00 16.70 5.50 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Kurd 0.00 0.00 12.20 0.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
Tajik 0.00 0.00 4.80 0.00 0.00 0.00 0.00 0.00 0.00 Khusainova et al. (2013) 
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Table 2.2: The C282Y, H63D and S65C allele frequencies in HFE characterised 
populations 
  Allele frequencies (%)  
Population Ethnicity C282Y H63D S65D References 
Myanmar Burmese 0.00 2.90 NT Viprakasit et al. (2004) 
Indonesia Indonesian 0.00 2.80 NT Merryweather-Clarke et al. 
(1997) 
Thailand Thais 0.00 3.20 NT Pointon et al. (2003) 
Vietnam Vietnamese 0.00 4.90 0.00 Pointon et al. (2003) 
Java Javanese 0.00 NT NT Cullen et al. (1998) 
Sri Lanka Sri Lankans 0.00 9.20 NT Merryweather-Clarke et al. 
(1997) 
Pakistan Pakistanis 0.00 8.00 NT Ali et al. (2018) 
China Chinese 
Han 
0.00 2.30 0.00 Lin et al. (2007) 
China Hong Kong 
Chinese 
0.00 2.80 NT Merryweather-Clarke et al. 
(1997) 






0.00 8.50 NT Merryweather-Clarke et al. 
(1997) 
Jordan Jordanian 0.00 11.25 0.11 Alkhateeb et al. (2009) 
India Indians 0.50 7.50 NT Nadkarni et al. (2017) 
Japan Japanese 0.00 0.99 NT Sohda et al. (1999) 
South Korea Koreans 0.00 3.80 NT Lee et al. (2000) 
Kirghizstan Kirghiz NT 8.10 0.00 Khusainova et al. (2013) 
Kurdistan Kurds NT 6.10 0.00 Khusainova et al. (2013) 
Turkmenia Turkmen NT 13.90 0.00 Khusainova et al. (2013) 
Kazakhstan Kazakhs NT 7.80 NT Khusainova et al. (2013) 
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Table 2.2: Cont. 
  Allele frequencies (%)  
Population Ethnicity C282Y H63D S65D References 
Uzbekistan Uzbeks NT 5.60 NT Khusainova et al. (2013) 
Tajikistan Tajiks NT 2.40 0.00 Khusainova et al. (2013) 
Israel Ashkenazi 
Jews 
1.62 14.08 NT Reish et al. (2010) 
Central Asia Uighurs 0.00 8.20 0.00 Khusainova et al. (2013) 
USA Caucasians 6.30 15.20 1.60 Beutler et al. (2000) 
USA Hispanics 2.70 12.40 0.60 Beutler et al. (2000) 
USA Asian 0.20 3.30 0.00 Beutler et al. (2000) 
USA Blacks 1.10 5.10 0.70 Beutler et al. (2000) 
Brazil Espiritos-
santense  
1.67 11.67 0.83 Alves et al. (2016) 
Brazil Brazilians 2.10 13.60 0.60 Santos et al. (2010) 
Ecuador Ecuadorians 0.00 3.50 4.00 Leone et al. (2005) 
Mexico Mexican 0.20 11.50 NT Avila-Gomez et al. (2008) 
Mexico Mexicans 0.00 6.50 NT Merryweather-Clarke et al. 
(1997) 
Venezuela Venezuelan 1.90 11.90 0.90 Avila-Gomez et al. (2008) 
Chile Chilean 1.28 10.58 NT Avila-Gomez et al. (2008) 
Columbia Columbians 0.00 0.00 NT Merryweather-Clarke et al. 
(1997) 
Jamaica Jamaicans 1.10 2.20 NT Merryweather-Clarke et al. 
(1997) 
Algeria Mozabites 0.00 8.90 NT Roth et al. (1997) 
Ethiopia  Ethiopians 0.00 9.40 NT Roth et al. (1997) 
Tunisia Tunisians 0.50 17.50 NT Zorai et al. (2003) 
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Table 2.2: Cont. 
  Allele frequencies (%)  
Population Ethnicity C282Y H63D S65D References 
Gambia Gambians 0.00 1.30 NT Merryweather-Clarke 
et al. (1997) 
Ghana  Ghanaians 0.00 1.00 NT Jeffery et al. (1999) 
Kenya Kenyans 0.00 1.30 NT Merryweather-Clarke 
et al. (1997) 
Nigeria Nigerians 0.00 1.90 NT Merryweather-Clarke 
et al. (1997) 
Senegal Senegalese 0.00 0.00 NT Merryweather-Clarke 
et al. (1997) 
South 
Africa 
South Africans 0.25 0.00 NT de Villiers et al. (1999) 
Zambia Zambians 0.00 0.70 NT Merryweather-Clarke 
et al. (1997) 
Australia Aborigines 0.00 0.00 NT Merryweather-Clarke 
et al. (1997) 
Australia Vanuatuans 0.00 0.60 NT Merryweather-Clarke 
et al. (1997) 
Sweden Finns, Swedes, 
Swedish 
Saamis 
2.00 7.90 3.00 Beckman et al. (2001) 
Sweden Swedish 6.10 12.40 1.60 Milman et al. (2005) 
Turkey Turks 0.00 13.57 NT Merryweather-Clarke 
et al. (1997) 
Spain Catalans 3.00 20.00 1.00 Altes et al. (2004) 
Spain Basque 3.60 30.40 NT Merryweather-Clarke 
et al. (1997) 
Spain Murcia 0.67 27.02 2.02 Avila-Gomez et al. 
(2008) 
Ireland Irish 14.00 17.90 NT Ryan et al. (1998) 
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Table 2.2: Cont. 
 
  Allele frequencies (%)  
Population Ethnicity C282Y H63D S65D References 
Hungary Hungarian 3.40 14.40 NT Andrikovics et al. 
(2001) 




2.00 7.90 3.00 Terzić et al. (2006) 
Czech 
Republic 
Czechs 3.40 16.20 1.25 Čimburová et al. 
(2005) 
Italy Apulians 1.50 14.00 0.50 Pietrapertosa et al. 
(2003) 
Italy Italians 3.20 13.40 1.30 Mariani et al. (2003) 
Italy  Modena 4.71 14.93 0.74 Salvioni et al. (2003) 
Italy Ossola 1.60 13.30 NT Cassanelli et al. 
(2001) 






1.60 15.70 1.60 Šarić et al. (2006) 
Croatia Croatians 3.30 14.50 1.80 Ristić et al. (2003) 
Slovenia Slovenians 4.00 14.50 0.50 Ristić et al. (2003) 
Slovenia Slovenian 
blood donors 
3.60 12.80 1.80 Cukjati et al. (2007) 
Portugal Madeirenses 0.33 20.50 1.00 Spínola et al. (2011) 
Portugal Portuguese 3.00 23.00 NT Porto et al. (1998) 
Germany Germans 3.80 13.20 NT Merryweather-
Clarke et al. (1997) 
Germany German blood 
donors 
4.60 10.80 NT Raddatz et al. (2003) 
Bulgaria Bulgarians 0.00 23.00 NT Merryweather-
Clarke et al. (1997) 
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Table 2.2: Cont. 
  Allele frequencies (%)  
Population Ethnicity C282Y H63D S65D References 
France North Africans 1.07 12.23 NT Aguilar-Martinez et 
al. (2001) 
France French 7.70 14.00 1.95 Mura et al. (1999) 
Finland Finns 4.60 9.80 2.30 Beckman et al. (2001) 
Poland Polish 3.10 16.20 NT Moczulski et al. 
(2001) 
Greece Greeks 1.30 13.50 NT Merryweather-Clarke 
et al. (1997) 
Austria Austrians 3.70 12.90 NT Merryweather-Clarke 
et al. (1997) 
Faroe 
Islands 
Faroese 8.00 17.50 1.00 Milman et al. (2005) 
UK British 8.10 15.20 NT Merryweather-Clarke 
et al. (1997) 
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2.4 Malay population in Peninsular Malaysia 
Malaysia is situated in Southeast Asia (SEA) and has thirteen states and three 
federal territories. The country is divided by the South China Sea into two regions (West 
Malaysia and East Malaysia) (Figure 2.4). West Malaysia (aka Peninsular Malaysia) 
has eleven states, and two federal territories while East Malaysia (aka Borneo) has two 
states and one federal territory (Mohd-Zaki et al., 2014). Peninsular Malaysia has a land 
size of 132,090 km2 which is approximately 40% while Borneo has a land size of 
198,847 km2 which is about 60% of the land area (Almayahi et al., 2013). 
Malaysia is a multi-ethnic nation that is inhabited by Malays, Chinese, Indians, 
Orang Asli and other minorities. The Orang Asli groups are further broken down into 
three subgroups such as Semang (Negrito), Senoi and Proto-Malays. Orang Asli, 
Malays and other indigenous people are called ‘Bumiputra’ (son of the soil). They are 
also grouped based on the languages of Aslian (Semang and Senoi) or Malayic (Malays 
and Proto-Malays) (Adelaar, 1993; Benjamin, 2012; Loo and Gan, 2014). 
Earlier studies identified the three classes of Orang Asli who migrated to 
Peninsular Malaysia in separate prehistoric times. Semang was the first Orang Asli 
group to arrive in Peninsular Malaysia some 50,000 years ago, and their ancestry forms 
the Aborigines in Australia, the Philippines and Papua New Guinea (Norhalifah et al., 
2016; Oppenheimer, 2011). Semang people currently speak the Aslian language 
originating from the Senoi people who migrated from Indochina roughly 7,000 years 
ago to Peninsular Malaysia (Hill et al., 2006; NurWaliyuddin et al., 2015).  Moreover, 
Proto-Malays, the third Orang Asli group, speaks a branch of Malayo-Polynesian 
subgroups of Austronesian languages called Malayic. Proto-Malays are thought to have 
migrated from Southern China about 5,000 years ago via Taiwan, the Philippines, 
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Indonesia, and Borneo and eventually reached Peninsular Malaysia around 3,000 years 
ago (Bellwood, 2007; Bellwood et al., 2011; Diamond, 2000). 
The present-day Malays known as Deutero-Malays in Peninsular Malaysia are 
descendants of some Proto-Malays admixed with Chinese, Indian and indigenous 
groups (Norhalifah et al., 2016; Yahya et al., 2017). 
 
Figure 2.4: Map of Malaysia showing the thirteen states and three federal 
territories. Figure modified from https://www.mapsofworld.com/malaysia/malaysia-
political-map.html. 
 





3.1 Study design 
This study analysed HFE SNP data on 35 Malay individuals. Malay 
populations have been the focus group of the study as they constitute the majority of 
the population (54.6%) in Malaysia along with Chinese (24.6%) and Indians (7.3%) as 
recorded in 2010 Population and Housing Census of Malaysia (Norhalifah et al., 
2016). A sample size of 35 has been targetted as it is within the agreed size of at least 
30 needed to predict 0.05 of allele frequencies within a probability of 95 per cent in 
population genetic studies (Fung and Keenan, 2014; Hale et al., 2012). Genomic DNA 
samples from these individuals were typed for C282Y, H63D and S65C by Edinur 
Atan’s research group at USM using PCR-RFLP methodology. The study was 
approved by the Human Ethical Committee of Universiti Sains Malaysia 
(USM/JEPeM/16050191) and the Malaysia Medical Research and Ethics Committee 
of the Ministry of Health (NMRR-16-1399-31311 (IIR) (Appendix A and B). Details 
of blood sample collection, DNA extraction, PCR-RFLP typing methodology and 
statistical analysis are described in the following sub-sections. 
3.2 Sample collection 
In 2018,  Norul Hajar Che Ghazali collected a total of 10 mL of blood samples 
from each of the Malay volunteers and kept in ethylenediaminetetraacetic acid 
(EDTA) tube. The volunteers were blood donors at three general hospitals in 
Peninsular Malaysia, namely Hospital Universiti Sains Malaysia (Kelantan), Hospital 
Seberang Jaya (Pulau Pinang), and Hospital Temerloh (Pahang). The following 
inclusion and exclusion criteria were applied for sample selection: 
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3.2.1 Inclusion criteria 
1. Unrelated healthy Malay blood donors. 
2. Adult (18 years and above). 
3. Male or female. 
4. Donors who voluntarily consent to participate and gave their signed written 
consent form. 
5. Donors with no history of intermarriage for at least three generations. 
3.2.2 Exclusion criteria 
1. Donors with a history of diseases. 
2. Donors who defer from blood donation. 
3. Non-Malays. 
3.3 DNA extraction from whole blood 
Genomic DNA was extracted from whole blood using a commercially 
available DNA extraction kit (Invisorb® Spin Forensic Kit) as previously described by 
Hajar et al. (Hajar et al., 2020). A minimum of 50 μL of whole blood was transferred 
into a 1.5 mL reaction tube and added with 10 μL and 50 μL of Proteinase K and Lysis 
Buffer M, respectively. The mixture was then incubated for 5 minutes at 56°C. Next, 
100 μL of binding buffer B6 was added to solution and subjected to pulse vortexing 
and centrifugation. 
Lysate was then transferred to the RTA spin filter membrane in a labelled 2 
mL RTA collection tube and centrifuged for 2 minutes at 11,000 x g. A total of 300 
μL wash buffer I was then added and again centrifuged for 1 minute at 11,000 x g. 
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Wash buffer II (750 μL) was then added to the RTA spin filter and centrifuged 
consecutively for 1 minute at 11,000 x g and for 4 minutes at full speed (18,000 x g) 
to remove both, wash buffer II and residual ethanol. The RTA spin filter was then 
transferred into a new 1.5 mL RTA receiver tube and added with 100 μL pre-warmed 
(56°C) elution buffer. This was followed by incubation for 1 minute at room 
temperature and centrifugation for 1 minute at 11,000 x g. RTA spin filter was then 
discarded and the extracted DNA was stored at -20°C until used. 
3.3.1 Agarose gel electrophoresis of extracted genomic DNA 
The extracted genomic DNA samples were fractionated using a 2% agarose gel 
electrophoresis. The agarose gel was prepared by mixing 4 g of agarose powder with 
200 mL of 0.5X TBE buffer in a 250 mL beaker. The solution mixture was then heated 
for 4 minutes in a microwave oven until the agarose powder fully dissolved.  
Agarose solution was then mixed with ethidium bromide (13 MgCl2 /mL) 
(Promega, USA) and poured onto the gel casting tray with a well-comb in place. The 
well-comb was removed after agarose gel solidified at room temperature. The 
solidified gel was placed in an electrophoresis tray and filled with 0.5X TBE buffer 
until it wholly submerged in the buffer solution. A mixture of 5 μL extracted genomic 
DNA and 1 μL DNA loading dye was loaded into the respective wells. The first well 
was loaded with the reference standard (3 μL of 100 bp DNA ladder) and 
electrophoresed for 45 minutes at 100V, and the presence of high molecular weight 
DNA was observed under UV light through a gel documentation system (Vilber 
Lourmat, Germany). 
23 
3.3.2 DNA quantitation 
The Nanodrop™ 1000 spectrophotometer (Thermo Scientific, USA) was used 
to determine the concentration and purity of each extracted genomic DNA sample. The 
sampling arm and lower pedestal were first cleaned using 2 μL of distilled water 
(dH2O) and wiped using Kimwipes. Then, 2 μL of elution buffer was loaded and 
measured as blank (0.00ng/μL). The same protocol was followed using 1 μL of DNA 
samples to measure DNA concentration and purity and was recorded. The absorbance 
of the DNA samples was calculated based on the reading of A260nm/A280nm ratio. 
High purity DNA samples are those within the acceptable range of 1.7 – 2.0Au. 
3.4 HFE typing using polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) 
HFE typing was done by using the PCR-RFLP technique. The PCR reaction 
mixture of 25 μL was prepared for each sample. Each of the reaction mixtures 
consisted of 2 μL of DNA sample with a concentration of 75 ng/μL to 125 ng/μL. Then 
continued with PCR amplification using thermal cycler machine. Furthermore, each 
of PCR products was digested with restriction enzymes. The details of genotyping for 
C282Y, H63D and S65C were described in the following subsection: 
3.4.1 Genotyping for C282Y 
Each PCR reaction mixture for amplification of a region containing C282Y 
SNP consists of 2 μL of DNA sample, 12.5 μL of Taq 2X Master Mix (BioLabs®, 
USA), 0.5 μL (0.5 μM) of forward (5′-CAA GTG CCT CCT TTG GTG AAG GTG 
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ACA CAT-3′) and reverse (5′-CTC AGG CAC TCC TCT CAA CC-3′) primers (1st 
BASE, Singapore) and 11.5 μL dH2O. 
The PCR-9700 thermal cycler machine (Applied Biosystems, USA) was used 
for amplification using the following thermal cycling parameters; initial denaturation 
at 94°C for 2 minutes, 10 cycles of denaturation at 94°C for 15 s and annealing at 65°C 
for 1 minute and 20 cycles of denaturation at 94°C for 15 s, annealing at 61°C for 50 
s and extension at 72°C for 30 s. 
The amplified PCR products were digested with RsaI enzymes (BioLabs®, 
USA) and incubated at 37°C for 15 minutes, followed by agarose gel electrophoresis. 
Amplification products containing C282Y SNP will produce 3 restriction fragments 
(203, 111, and 29 bp) while the wild type produced two restriction fragments (203 and 
140 bp). Those restriction fragments were visualised under ultraviolet (UV) light using 
a gel documentation system (Vilber Lourmat, Germany). 
3.4.2 Genotyping for H63D 
Each PCR reaction mixture for amplification of a region containing H63D SNP 
consist of 2 μL of DNA sample, 12.5 μL of Taq 2X Master Mix (BioLabs®, USA), 0.5 
μL (0.5 μM) of forward (5′-ACA TGG TTA AGG CCT GTT GC-3′) and reverse (5′-
CTT GCT GTG GTT GTG ATT TTC C-3′) primers (1st BASE, Singapore) and 11.5 
μL dH2O. 
PCR cycling parameters as described earlier (sub-section 3.4.1). The amplified 
PCR products were digested with MboI enzymes (BioLabs®, USA) and incubated at 
37°C for 15 minutes, preceded by agarose gel electrophoresis. Amplification products 
containing H63D SNP will produce two restriction fragments (237 and 57 bp) while 
